Prescient Collaborates with Carina Biotech in Expansion into Exciting CAR-T Therapies

Prescient Therapeutics Limited (ASX: PTX) develops personalised medicine approaches to address mutations that cause cancer. The Company employs a targeted therapy approach to target individual tumour variability rather than the conventional one size fits all treatment approach in which patients are treated the same irrespective of the differences between individuals.

Prescient had recently entered into a collaboration with an Australian Biotech company, Carina Biotech headquartered in Adelaide for development of exciting new CAR-T approaches for cancer treatment.

Carina Biotech is engaged in R&D of an effective broad-spectrum Chimeric Antigen Receptor T cell (CAR-T) therapy to treat solid cancers with its lead product CAR-T cell, CNA1003, which is targeted at a marker found on a wide range of solid tumours, however mostly absent from healthy tissues.

Pioneering CAR-T Therapy

CAR-T Cell Therapy is a ground-breaking and novel approach to treat cancer that utilises patient’s own immune system to target and attack cancer, wherein patients’ T cells are separated, re-engineered and introduced back to the body as depicted in below figure.

CAR-T therapies have drawn global medical and investors interest since 2017 -

Another company that is operating in similar CAR-T medicine space is Juno Therapeutics which was acquired by Celgene in a US$9 B deal in January 2018. Recently, Bristol-Myers Squibb completed a US$74 B acquisition of Celgene in November 2019.

Prescient’s Collaboration with Carina Biotech Addresses the Current Challenges of CAR-T Technologies

This collaboration will bring together Prescient’s expertise in targeted therapies with Carina Biotech’s promising cell therapies to improve CAR-T approaches to treat an array of cancers, in turn, offering a vast area of opportunity while seeking to address some of the current challenges of CAR-T therapy. No additional capital would be required to carry out the work as it would be undertaken within Prescient’s existing budget. While the exact terms and conditions of the agreement and collaboration remain confidential, any consequential IP arising from this alliance would be shared by both Prescient and Carina.

Driving Force Behind the Collaboration

Both Prescient and Carina biotech are backed by a strong management team.

Mr Yatomi-Clarke, Managing Director and CEO of Prescient Therapeutics, commented-

Looking forward to working with Carina’s world-class scientists, he further added that the association with Carina Biotech would leverage Prescient’s knowledge of biochemical pathways, and targeted therapies, and their role in the immune system. Leveraging Carina Biotech’s unique and novel technologies to engineer next generation cell therapy will further help in diversifying Presceint’s portfolio into the exciting CAR-T space, thereby strengthening Prescient’s overall product pipeline.

Dr Justin Coombs, MD, Carina Biotech mentioned that the initial pre-clinical study findings from Carina’s CAR T-cells targeting solid tumours unveiled positive outcomes. To boost the response rate in solid tumours, the Company is further actively exploring several approaches.

Commenting further on the benefits of this collaboration he stated-

Other key representatives of the Prescient team have vast experience in bringing in innovative oncology therapies to market with top international firms such as Array BioPharma, GSK and Pfizer.

To know more about Prescient Therapeutics Limited, click here.

To stay updated with PTX company activities and announcements, please update your details on their investor centre.

Disclaimer

This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. The above article is sponsored but NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) under discussion. We are neither licensed nor qualified to provide investment advice through this platform.